Education
About Us
Working with TipRanks
Follow Us
Gyre Therapeutics (GYRE)
NASDAQ:GYRE
GYRE Stock Chart & Stats
$6.81
-$0.21(-2.15%)
At close: 4:00 PM EST
$6.81
-$0.21(-2.15%)
Day’s Range― - ―
52-Week Range$6.11 - $13.75
Previous CloseN/A
Volume104.17K
Average Volume (3M)102.52K
Market Cap
$699.86M
Enterprise Value$739.30M
Total Cash (Recent Filing)$40.40M
Total Debt (Recent Filing)$1.17M
Price to Earnings (P/E)201.6
Beta1.83
Next Earnings
Mar 31, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding90,890,380
10 Day Avg. Volume112,833
30 Day Avg. Volume102,519
Financial Highlights & Ratios
PEG Ratio-0.78
Price to Book (P/B)16.26
Price to Sales (P/S)9.74
P/FCF Ratio-172.88
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue6.89
Enterprise Value/Gross Profit7.22
Enterprise Value/Ebitda49.18
Forecast
1Y Price Target
$19.00Price Target Upside179.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development StrategyA planned U.S. Phase 2 assessment for MASH and a brief trial start delay allow incorporation of existing data to reduce risk for subsequent clinical programs.
Clinical EfficacyLate-stage trials in China showed promising safety and efficacy signals for hydronidone in chronic hepatitis B–associated liver fibrosis, supporting confidence in the drug's anti‑fibrotic activity.
Pipeline DiversificationCompletion of enrollment in a Phase 3 study of pirfenidone for pneumoconiosis and a portfolio of clinical and commercial stage therapies broaden potential revenue streams beyond a single asset.
Bears Say
Clinical Trial Failure RiskOngoing and future pivotal trials carry the risk of failing to meet primary endpoints, which would materially weaken clinical and commercial prospects.
Competition RiskMultiple peers developing anti‑fibrotic treatments create competitive pressure that could reduce market share and pricing power if several therapies reach the market.
Regulatory RiskDependence on conditional approval pathways and additional confirmatory trials means regulators could impose stricter requirements or delays that limit or postpone market access.
Gyre Therapeutics News
GYRE FAQ
What was Gyre Therapeutics’s price range in the past 12 months?
Gyre Therapeutics lowest stock price was $6.11 and its highest was $13.75 in the past 12 months.
What is Gyre Therapeutics’s market cap?
Gyre Therapeutics’s market cap is $699.86M.
When is Gyre Therapeutics’s upcoming earnings report date?
Gyre Therapeutics’s upcoming earnings report date is Mar 31, 2026 which is in 73 days.
How were Gyre Therapeutics’s earnings last quarter?
Gyre Therapeutics released its earnings results on Nov 07, 2025. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.047 by -$0.017.
Is Gyre Therapeutics overvalued?
According to Wall Street analysts Gyre Therapeutics’s price is currently Undervalued.
Does Gyre Therapeutics pay dividends?
Gyre Therapeutics pays a Quarterly dividend of $3.6 which represents an annual dividend yield of N/A. See more information on Gyre Therapeutics dividends here
What is Gyre Therapeutics’s EPS estimate?
Gyre Therapeutics’s EPS estimate is 0.06.
How many shares outstanding does Gyre Therapeutics have?
Gyre Therapeutics has 90,890,380 shares outstanding.
What happened to Gyre Therapeutics’s price movement after its last earnings report?
Gyre Therapeutics reported an EPS of $0.03 in its last earnings report, missing expectations of $0.047. Following the earnings report the stock price went down -1.771%.
Which hedge fund is a major shareholder of Gyre Therapeutics?
Currently, no hedge funds are holding shares in GYRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gyre Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.79%
12-Months-Change
Fundamentals
Return on Equity
8.06%
Trailing 12-Months
Asset Growth
26.23%
Trailing 12-Months
Company Description
Gyre Therapeutics
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
GYRE Stock 12 Month Forecast
Average Price Target
$19.00
▲(179.00% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Terns Pharmaceuticals
―
Day One Biopharmaceuticals
―
Tyra Bioscience
―
MBX Biosciences, Inc.
―
Ownership Overview
3.87% Insiders
1.64% Mutual Funds
<0.01% Other Institutional Investors
92.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---